Compare InMode Ltd (INMD) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs Smith & Nephew plc — how do they compare? InMode Ltd trades at $15.19 (market cap $876.40M), while Smith & Nephew plc trades at $30.14 (market cap $12.38B). The key difference: Smith & Nephew plc is far larger — about 14.1× InMode Ltd's market cap, and Smith & Nephew plc pays a 2.66% dividend while InMode Ltd pays none. Which is the better fit depends on your goals.
| INMD | SNN | |
|---|---|---|
Market Cap | $876.40M | $12.38B |
Sector | Technology | Health |
52-Week High | $16.62 | $38.70 |
52-Week Low | $12.76 | $28.73 |
Enterprise Value | $379.73M | $15.41B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INMD trades at $15.23, up 0.59% on the day, with a neutral technical signal and mixed earnings history including a Q1 2026 miss. Valuation ratios appear attractive with a P/E of 12.59 and EV/EBITDA of 5.43, while profitability remains strong with a net income margin of 20.69%. Recent news highlights an unsolicited acquisition offer from Steel Partners at $16.75 per share and ongoing shareholder disputes.
The stock presents a cautious opportunity given its undervaluation and robust cash flow, but risks include earnings volatility, governance tensions, and a securities fraud investigation. Analyst consensus is divided with 45% buy ratings, reflecting uncertainty around the acquisition outcome and future execution.
SNN trades at $30.11, up 0.33% today, with a bearish technical signal but improving fundamentals. Recent earnings show mixed results, beating in Q4 2025 and Q2 2026 but missing earlier quarters. Revenue growth has accelerated from $5.2B in 2022 to $6.16B in 2025, with net income margin expanding to 10.08%. The company maintains a dividend, with the next payment scheduled for November 2026. News highlights include product launches in robotics and wound care, though Q2 2026 revenue growth fell short of expectations.
Outlook is cautiously optimistic due to solid profitability and innovation, but risks include U.S. market softness and competitive pressures. Analysts largely recommend Hold, reflecting balanced growth potential against execution challenges. The stock's valuation at a P/E of 20.3 appears reasonable if earnings momentum continues, but investors should monitor operational execution closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
